Today: 11 June 2026
Salesforce stock rises as RBC lifts target; $250 level and jobs report loom
6 January 2026
1 min read

Salesforce stock rises as RBC lifts target; $250 level and jobs report loom

New York, Jan 5, 2026, 21:06 EST — Market closed

  • Salesforce shares rose about 1% on Monday, snapping a three-day losing streak.
  • RBC Capital lifted its Salesforce price target to $290, citing more visible enterprise AI demand in 2026.
  • Investors are bracing for Friday’s U.S. jobs report and looking ahead to Salesforce’s next earnings window.

Salesforce shares rose 1.1% to $256.26 on Monday, snapping a three-session slide. The customer-relationship-management software maker is still about 30% below its 52-week high and traded lighter-than-average volume, according to MarketWatch data.

The move comes as Wall Street tries to pin down which large-cap software names can turn “AI agents” — software that can take actions on a user’s behalf — into billable growth. RBC Capital Markets analyst Rishi Jaluria raised his price target on Salesforce to $290 from $250 and kept a Sector Perform rating, roughly a hold call. TipRanks

“2026 is likely to be a year when AI tailwinds become more evident” for companies positioned for enterprise adoption, Jaluria wrote. He said enterprise spending looked steadier in pockets even as management teams stayed conservative in early-2026 outlooks. TipRanks

Salesforce’s gains tracked a broader risk-on session that pushed the Dow to a record close, helped by strength in energy and financials after a U.S. operation in Venezuela, Reuters reported. The rally left investors toggling between geopolitics, growth stocks and the next round of U.S. data.

Within mega-cap tech, Salesforce outperformed Microsoft on the day and edged Alphabet’s two share classes, MarketWatch data showed. In enterprise software, ServiceNow was up slightly while Oracle fell, underscoring the uneven tone in the group.

The next company-specific scoreboard remains bookings and backlog. In December, Salesforce raised full-year fiscal 2026 revenue guidance to $41.45 billion to $41.55 billion and flagged current remaining performance obligation (cRPO) — a key contracted backlog measure — of $29.4 billion, up 11%.

Investors also have a nearer-term calendar item: Salesforce is due to pay a quarterly cash dividend of $0.416 per share on Jan. 8, the company said.

Macro data may set the tone for the next session. The U.S. employment report for December is scheduled for Friday, Jan. 9 at 8:30 a.m. ET, according to the Bureau of Labor Statistics.

Technically, traders have focused on the $250 area after the stock’s recent pullback. MarketBeat data put Salesforce’s 50-day moving average near $249.78, with the 200-day near $251.55, while Monday’s range ran from $252.49 to $259.55.

But the setup carries a clear risk: if rate expectations reset higher after the jobs data, high-multiple software stocks can slide quickly, even without company news. And if AI features take longer to translate into incremental subscription demand, investors may push back on valuations and guidance.

The market’s next checkpoints are Thursday’s dividend payment and Friday’s jobs report, before attention turns to Salesforce’s next results, which Nasdaq data estimates around Feb. 25.

Stock Market Today

  • AMD Stock Price Forecast: Analyst Lowers Target Amid AI Market Caution
    June 11, 2026, 11:00 AM EDT. Shares of Advanced Micro Devices (AMD) have surged 111% year-to-date, driven by investor optimism over its expanding role in the artificial intelligence (AI) sector. Despite the strong performance, a prominent AI-focused analyst has trimmed the price target for AMD, signaling caution about the chipmaker's near-term prospects. The analyst cited concerns over competitive pressures and potential market saturation. AMD's growth is largely tied to its ability to capture demand in AI computing, a fast-evolving field requiring specialized semiconductor technology. Investors are weighing the company's robust sales against risks from supply chain constraints and intensifying industry competition.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Why MercadoLibre (MELI) stock jumped nearly 9% on Venezuela shock headlines
Previous Story

Why MercadoLibre (MELI) stock jumped nearly 9% on Venezuela shock headlines

Marks & Spencer (MKS.L) shares fall as Jan 8 Christmas trading update looms
Next Story

Marks & Spencer (MKS.L) shares fall as Jan 8 Christmas trading update looms

Go toTop